MECHELEN, BELGIUM and SAFFRON WALDEN, UK--(Marketwire - October 14, 2010) - Galapagos NV
(Euronext: GLPG) announced today that its BioFocus service division has
a collaboration with Chiesi Farmaceutici, a privately held
pharmaceutical company. Total value for the collaboration with Chiesi
reached EUR2.5 million.
BioFocus and Chiesi began their collaboration in December 2009 and
extended it for one year. Under the terms of the extended
agreement, BioFocus will provide medicinal chemistry and biology services,
an additional option for ADME services, for an undisclosed Chiesi
"BioFocus has a high return business rate with clients, and we are pleased
Chiesi has chosen to extend this successful collaboration," said Onno van
Stolpe, CEO of Galapagos. "The quality of the science at BioFocus enables
sustain its position as a premier provider in drug discovery services."
"The medicinal chemistry and biology work performed by BioFocus so far
us to accelerate progress on our therapeutic programs. We look
working with BioFocus to move these programs forward toward the clinic,"
Paolo Chiesi, R&D Director and Vice-President of Chiesi Farmaceutici.
About Chiesi Farmaceutici
With over 3,500 employees around the world, the Chiesi Group
distributes successful drugs in 65 countries, and is present on 5
with 24 direct affiliates, 4 research centres, and 3 production
Respiratory pathologies, special care medicine, and cardiovascular
its traditional areas of expertise where it offers many therapeutic
recognized for their effectiveness. More info at: www.chiesigroup.com
BioFocusaims to expand its partners' drug pipelines by accelerating the
drug candidate discovery process. This is achieved through a comprehensive
discovery platform, which includes target discovery in human primary cells,
focused as well as diverse compound libraries, in vitro and cell-based
screening, structural biology, medicinal chemistry, ADME/PK services,
by unique chemogenomic and informatics tools, and compound library
storage and distribution services. As a service division of Galapagos,
has over 250 employees in four countries worldwide. More info at:
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of the
largest pipelines in biotech, with six clinical and over 50 small molecule
discovery/pre-clinical programs. Through risk/reward-sharing alliances with
GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Merck & Co., Roche and
Galapagos is eligible to receive up to EUR3.3 billion in downstream
plus royalties. Following the acquisition of the Zagreb research center,
Galapagos Group now has over 800 employees and operates facilities in seven
countries, with global headquarters in Mechelen, Belgium. More info
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
looking statements may involve known and unknown risks, uncertainties and
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly
obligation to update any such forward-looking statements in this
reflect any change in its expectations with regard thereto or any
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE